Abpro Corporation (ABP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abpro Corporation (ABP) trades at $0.52 with AI Score 58/100 (Hold). Abpro Corporation is a biotechnology company focused on developing novel antibody constructs for immuno-oncology and ophthalmology. Market cap: 2M, Sector: Healthcare.
Last analyzed: Mar 3, 2026Abpro Corporation (ABP) Healthcare & Pipeline Overview
Abpro Corporation pioneers next-generation antibody therapies for cancer and ophthalmic diseases, leveraging its innovative DiversImmune and MultiMab platforms to create multi-specific antibodies with the potential to transform treatment paradigms and address unmet medical needs in oncology and vascular diseases.
Investment Thesis
Abpro presents a notable research candidate due to its innovative MultiMab platform and promising pipeline of TetraBi antibody therapeutics. The company's lead candidates, ABP-102 and ABP-201, target significant unmet needs in oncology and ophthalmology, respectively. Positive preclinical data and potential for clinical success could drive significant value appreciation. The strategic partnerships with Celltrion and Abpro Bio International further validate the company's technology and provide potential revenue streams. While the company's current negative profitability (Profit Margin: -7670.5%) poses a risk, successful clinical trials and subsequent commercialization could significantly improve financial performance. Investing in Abpro is a high-risk, high-reward proposition, contingent on the successful development and regulatory approval of its therapeutic candidates. The company's focus on novel antibody constructs offers a differentiated approach in competitive markets.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead product candidate ABP-102 targets HER2+ solid tumors, including breast and gastric cancers, addressing a significant market with unmet needs.
- ABP-201, another lead candidate, aims to treat vascular diseases of the eye, such as diabetic macular edema and wet age-related macular degeneration, offering a novel therapeutic approach.
- The company's DiversImmune and MultiMab platforms provide a competitive advantage in generating and engineering multi-specific antibodies.
- Strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. validate the company's technology and provide potential for future collaborations and revenue streams.
- Abpro's focus on TetraBi antibody format allows for simultaneous targeting of multiple disease pathways, potentially leading to more effective treatments.
Competitors & Peers
Strengths
- Proprietary DiversImmune and MultiMab platforms.
- Novel TetraBi antibody format.
- Pipeline of therapeutic candidates targeting unmet medical needs.
- Strategic partnerships with Celltrion and Abpro Bio International.
Weaknesses
- Limited financial resources.
- Negative profitability and high operating expenses.
- Reliance on successful clinical development and regulatory approval.
- Small number of employees.
Catalysts
- Upcoming: Clinical trial results for ABP-102 in HER2+ solid tumors.
- Upcoming: Clinical trial results for ABP-201 in diabetic macular edema and wet age-related macular degeneration.
- Upcoming: Announcement of new strategic partnerships or collaborations.
- Ongoing: Continued development of ABP-110 and ABP-150.
- Ongoing: Expansion of the DiversImmune and MultiMab platforms.
Risks
- Potential: Clinical trial failures for ABP-102, ABP-201, ABP-110, and ABP-150.
- Potential: Regulatory setbacks and delays in obtaining marketing approvals.
- Ongoing: Competition from larger pharmaceutical and biotechnology companies.
- Ongoing: Need for additional financing, potentially diluting existing shareholders.
- Ongoing: High cash burn rate and limited financial resources.
Growth Opportunities
- Expansion of ABP-102 into additional HER2+ solid tumor indications: The success of ABP-102 in breast and gastric cancers could pave the way for its application in other HER2-expressing tumors, such as lung and ovarian cancers. This expansion would significantly increase the potential market size for ABP-102 and drive revenue growth. The timeline for this expansion depends on the results of ongoing and future clinical trials.
- Advancement of ABP-201 through clinical trials: Positive results from clinical trials of ABP-201 for diabetic macular edema and wet age-related macular degeneration would be a major catalyst for growth. Successful clinical development could lead to regulatory approval and commercialization, capturing a significant share of the growing market for ophthalmic therapeutics. The timeline for clinical trials and regulatory approval is estimated to be several years.
- Development of ABP-110 and ABP-150 for hepatocellular carcinoma and gastric cancers: These pipeline candidates offer additional growth potential in the oncology market. Successful development and commercialization of these therapies would diversify Abpro's product portfolio and increase its revenue streams. The timeline for these programs depends on preclinical and clinical development progress.
- Strategic partnerships and collaborations: Abpro can leverage its DiversImmune and MultiMab platforms to establish new partnerships with pharmaceutical companies for the development of novel antibody therapeutics. These collaborations would provide upfront payments, milestone payments, and royalties, contributing to revenue growth and validating the company's technology. The timing and success of these partnerships are uncertain.
- Expansion into new therapeutic areas: Abpro's antibody engineering capabilities can be applied to develop therapeutics for other diseases beyond oncology and ophthalmology. This expansion would diversify the company's product portfolio and reduce its reliance on specific therapeutic areas. The timeline for this expansion depends on the company's strategic priorities and resource allocation.
Opportunities
- Expansion of ABP-102 into additional indications.
- Advancement of ABP-201 through clinical trials.
- Development of ABP-110 and ABP-150.
- Establishment of new strategic partnerships.
Threats
- Competition from larger pharmaceutical and biotechnology companies.
- Clinical trial failures and regulatory setbacks.
- Dilution of existing shareholders through future financings.
- Economic downturn impacting research and development funding.
Competitive Advantages
- Proprietary DiversImmune and MultiMab platforms for antibody discovery and engineering.
- TetraBi antibody format offering multi-specific targeting capabilities.
- Strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc.
- Pipeline of novel antibody therapeutics targeting unmet medical needs.
About ABP
Abpro Holdings, Inc., established in 2004 and headquartered in Woburn, Massachusetts, is a biotechnology company dedicated to the discovery and development of novel antibody constructs. The company focuses primarily on immuno-oncology and ophthalmology, utilizing its proprietary DiversImmune and MultiMab platforms to create innovative therapeutic candidates. DiversImmune serves as a discovery engine, generating a diverse library of proprietary antibodies against clinically validated and novel targets. MultiMab, on the other hand, is an engineering platform that allows for the flexible combination of antibody building blocks, enabling the creation of fit-for-purpose, full-length multi-specific antibody constructs. Abpro's lead product candidates include ABP-102, a TetraBi antibody targeting HER2 and CD3 for HER2+ solid tumors, and ABP-201, a TetraBi antibody inhibiting VEGF and ANG-2 for vascular diseases of the eye. Additionally, the company is developing ABP-110, targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, targeting claudin 18.2 and CD3 for gastric cancers. Abpro has established strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc., furthering its research and development efforts and expanding its market reach. The company's focus on multi-specific antibody technology positions it at the forefront of innovative therapeutic development.
What They Do
- Develops novel antibody constructs for immuno-oncology.
- Creates antibody therapies for ophthalmology.
- Utilizes the DiversImmune platform to discover proprietary antibodies.
- Employs the MultiMab platform to engineer multi-specific antibodies.
- Focuses on TetraBi antibody format for targeted therapies.
- Targets HER2+ solid tumors with ABP-102.
- Develops ABP-201 for vascular diseases of the eye.
- Creates ABP-110 for hepatocellular carcinoma and ABP-150 for gastric cancers.
Business Model
- Discovers and develops novel antibody therapeutics.
- Out-licenses or partners its therapeutic candidates with larger pharmaceutical companies.
- Generates revenue through upfront payments, milestone payments, and royalties from partnerships.
- Potentially commercializes its own products upon regulatory approval.
Industry Context
Abpro operates within the competitive biotechnology industry, specifically targeting the immuno-oncology and ophthalmology markets. The immuno-oncology market is experiencing rapid growth, driven by the increasing prevalence of cancer and the demand for more effective and targeted therapies. Similarly, the ophthalmology market is expanding due to the aging population and the rising incidence of vascular diseases of the eye. Abpro's multi-specific antibody technology positions it to compete with larger pharmaceutical companies and other biotechnology firms developing novel therapeutics in these areas. Competitors include companies like AEON, APM, BOLT, CING, and CLRB, all vying for market share in these high-growth sectors.
Key Customers
- Pharmaceutical companies seeking novel antibody therapeutics.
- Patients suffering from cancer and vascular diseases of the eye.
- Healthcare providers prescribing Abpro's therapies.
Financials
Chart & Info
Abpro Corporation (ABP) stock price: $0.52 (-0.03, -0.77%)
Latest News
-
Is Abpro Holdings Inc Gaining or Losing Market Support?
benzinga · Feb 12, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Feb 12, 2026
-
Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
benzinga · Feb 12, 2026
-
Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4%
defenseworld.net · Feb 12, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABP.
Price Targets
Wall Street price target analysis for ABP.
MoonshotScore
What does this score mean?
The MoonshotScore rates ABP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Is Abpro Holdings Inc Gaining or Losing Market Support?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4%
What Investors Ask About Abpro Corporation (ABP)
What does Abpro Corporation (ABP) do?
Abpro Corporation (ABP) is a biotechnology company focused on developing innovative antibody therapies for cancer and eye diseases. They utilize their proprietary DiversImmune and MultiMab platforms to create multi-specific antibodies that can target multiple disease pathways simultaneously. Their lead product candidates, like ABP-102 and ABP-201, are designed to address unmet medical needs in oncology and ophthalmology, offering potential for more effective and targeted treatments compared to existing therapies. This positions Abpro as a key player in the next generation of antibody therapeutics.
Is ABP stock worth researching?
Evaluating whether ABP stock is worth researching requires careful consideration. The company's innovative technology and promising pipeline offer significant potential, but it also carries substantial risk. With a negative profit margin of -7670.5% and a small market cap, ABP is a high-risk, high-reward investment. Positive clinical trial results for its lead candidates and strategic partnerships could drive significant value appreciation. Investors should weigh the potential upside against the risks associated with biotechnology investments, including clinical trial failures and regulatory hurdles, before making a decision.
What are the risks of investing in ABP?
Investing in Abpro (ABP) carries several risks inherent to biotechnology companies. A primary risk is the potential for clinical trial failures, which could significantly impact the company's valuation. The company's high cash burn rate and negative profit margin (-7670.5%) necessitate additional financing, potentially leading to dilution of existing shareholders. Regulatory hurdles and competition from larger pharmaceutical companies also pose significant challenges. Investors should carefully assess these risks before investing in ABP.
What catalysts could move ABP stock?
Several catalysts could significantly impact ABP stock. Positive results from ongoing clinical trials for ABP-102 and ABP-201 would be major catalysts, validating the company's technology and increasing investor confidence. The announcement of new strategic partnerships or collaborations with larger pharmaceutical companies could also drive the stock price higher. Furthermore, any progress in the development of ABP-110 and ABP-150, such as the initiation of clinical trials, could serve as positive catalysts. These upcoming events have the potential to significantly alter the trajectory of ABP stock.
What is ABP stock price target?
As of March 3, 2026, there is no readily available analyst consensus price target for ABP stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed financial model, considering factors such as the potential market size for its lead product candidates, the probability of clinical trial success, and the company's cash flow projections. Investors should conduct their own due diligence and consider the inherent risks and uncertainties before making an investment decision.
What are the key factors to evaluate for ABP?
Abpro Corporation (ABP) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary DiversImmune and MultiMab platforms.. Primary risk to monitor: Potential: Clinical trial failures for ABP-102, ABP-201, ABP-110, and ABP-150.. This is not financial advice.
How frequently does ABP data refresh on this page?
ABP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ABP's recent stock price performance?
Recent price movement in Abpro Corporation (ABP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary DiversImmune and MultiMab platforms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.